TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT06408259: A Phase 3, Multicenter, Double-blind, Active-controlled Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Oral Ozanimod Compared to Oral Fingolimod in Children and Adolescent

Sponsor: Bristol-Myers Squibb · Phase: PHASE3 · Area: CNS_NEUROLOGY · Target Enrollment: 194 pts

Competing Trials Overlap

8 Active Trials

Excess Burn Exposure

$12,616,984

Rescue Site Savings

+$8,319,496

Unlock Full NCT06408259 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06408259 Rescue Dossier →